Showing 3961-3970 of 6805 results for "".
- CBD Brands Initiates AD studyhttps://practicaldermatology.com/news/cbd-brands-initiates-ad-study-1/2460226/In the wake of the US Food and Drug Administration’s (FDA) recent revised warning about the risks of CBD products, CBD Brands is initiating a study to investigate a novel cannabidiol lotion for the treatment of atopic dermatitis (AD). The study aims to provide a preliminary assess
- Revance Files BLA for DAXIhttps://practicaldermatology.com/news/revance-files-bla-for-daxi/2460224/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under the current Pres
- Baring Private Equity Asia Agrees to Acquire Lumenishttps://practicaldermatology.com/news/baring-private-equity-asia-agrees-to-acquire-lumenis-1/2460222/Baring Private Equity Asia’s affiliated private equity funds are acquiring Lumenis. The transaction, which values Lumenis at an enterprise value of more than $1 billion, remains subject to the customary regulatory approval process. It is expected to be completed in early 2020. <
- Citing Underperformance, Hologic Sells Cynosure Medical Aesthetics Business for $205Mhttps://practicaldermatology.com/news/hologic-to-sell-cynosure-medical-aesthetics-business-for-205m/2460221/Hologic is selling Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments. This is a tenth of the $1.6B that Hologic, a women's&n
- Celebrate National Botox Day on November 20, 2019https://practicaldermatology.com/news/celebrate-national-botox-day-on-november-20th-2019/2460218/Mark your calendars: November 20, 2019 will be the first-ever National Botox Cosmetic Day. Why Nov. 20? It is the busiest day on record for booking Botox cosmetic treatments in the US. And to commemorate it, Allergan is offering an exclusive deal for one day only where patien
- Post-Market Price Changes Alone Account for Most Recent Spending Growth for Biologics, and Rebates Have Little Impacthttps://practicaldermatology.com/news/post-market-price-changes-alone-account-for-most-recent-spending-growth-for-biologics-and-rebates-have-little-impact/2460214/Annual spending on biologics by U.S. public programs and beneficiaries nearly doubled from 2012 to 2016, according to research presented
- Live Zoster Vaccine Safe and Effective for Patients on TNF Blockershttps://practicaldermatology.com/news/live-zoster-vaccine-safe-and-effective-for-patients-on-tnf-blockers/2460213/The live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications, according to
- Researchers Elucidate Why Some Beta Blockers May Trigger or Exacerbate Psoriasishttps://practicaldermatology.com/news/researchers-elucidate-why-some-beta-blockers-may-trigger-or-exacerbate-psoriasis/2460211/Beta-blockers can trigger or exacerbate psoriasis, and now scientists at the University of Bonn and Freie Universität Berlin may know why. It appears that beta-blockers can interfere with the breakdown of defective cell components. In return, the cells release messengers that trigger immune-
- LEO Science & Tech Hub and Epicore Biosystems Advance AD Collabhttps://practicaldermatology.com/news/leo-science-tech-hub-and-epicore-biosystems-advance-ad-collab/2460208/LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma A/S, is starting the next phase of a research collaboration in atopic dermatitis (AD) with Epicore Biosystems, a wearable microfluidics and biosensor spinout from Northwestern University’s Center for Bio-Inte
- Arcutis Biotherapeutics Plans to Initiate Phase 3 Program for ARQ-151 for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-biotherapeutics-plans-to-initiate-phase-3-program-for-arq-151-for-plaque-psoriasis/2460196/Arcutis Biotherapeutics, Inc. plans to initiate its Phase 3 program of ARQ-151 as a potential topical treatment for plaque psoriasis following its End-of-Phase 2 meeting with the FDA. The Company anticipates initiating a Phase 3 clinical trial in the first half of 2020. Frank Watanabe,